NZYM B Novozymes A/S Class B

Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook

Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook

COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook.

The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter.

Ester Baiget, President & CEO, says:

“We started the year with strong sales growth and earnings. This is a testament to our innovative solutions, resilient global business model, and our ability to continue to meet the increasing demand for biosolutions in an ever-changing world.”

“Emerging markets were a key growth driver, and all our four sales areas grew by double digits. We’re pleased with our progress, and we maintain our full-year financial outlook.”

“Overall, our Q1 performance underscores the value of our solutions in helping customers do more with less—enabling higher yields, improved throughput, enhanced performance, and greater benefits. And it shows that growth and planet stewardship can be two sides of the same coin.”

During the first three months of the financial year, Novonesis launched six innovations including an advanced protease portfolio for swift and efficient stain removal.

Divisional sales performance organic

In the first three months of the financial year, Food & Health Biosolutions grew by 12%, while Planetary Health Biosolutions grew by 11%. 

In Food & Health Biosolutions, Food & Beverages grew by 11% with double-digit growth across most categories. In Human Health, organic sales growth was 13% driven by a strong development in Dietary Supplements.

In Planetary Health Biosolutions, Household Care grew by 12%. The strong performance was driven by increased penetration and innovation. Agriculture, Energy & Tech grew by 10% driven by double-digit growth in Energy and Tech.

Regional performance organic

For the first quarter, emerging markets grew by 15% driven by all sales areas. Developed markets grew by 9%, driven by innovation.

For Q1 2025, organic growth rates by geography were 14% in Europe, Middle East & Africa, 7% in North America, 9% in Asia Pacific, and 18% in Latin America.

Outlook for 2025

The 2025 outlook is maintained at 5-8% organic sales growth (6-9% excluding the exit from certain countries) and an adjusted EBITDA margin between 37-38% despite current currency headwinds.

The 2025 outlook is based on current levels of global trade tariffs. Our strong global setup, including flexible regional production capabilities, creates a diversified and resilient business. Additionally, we have confidence in passing on incremental cost driven by tariffs. As a result, we expect no or only marginal net impact from tariffs.

Financial calendar 2025 / 2026

  • August 21, 2025: H1 2025 financial results
  • November 6, 2025: Q3 2025 financial results
  • February 25, 2026: Full-year financial statement 2025
Media Relations  Investor Relations
Anne Sophie Scavenius

Senior Media Relations Manager

Phone:





 
  Tobias Cornelius Björklund

Head of Investor Relations

Phone:

Attachments



EN
08/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full annuncement in PDF. Attachment

 PRESS RELEASE

Invitation to the 2026 Annual General Meeting

Invitation to the 2026 Annual General Meeting The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark. For further information, please refer to the enclosed invitation to convene the Annual General Meeting, including the agenda and complete proposals. BOARD OF DIRECTORSThe Board of Directors proposes the re-election of Cornelis (Cees) de Jong as Chair of the Board and Heine Da...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The Executive Leadership Team members eligible for the Novozymes A/S 2023-2025 incentive program has on February 25, 2026, received the allocated shares. An overview of the number and value of shares allotted is provided...

 PRESS RELEASE

Novonesis delivered strong organic sales growth of 7% in 2025

Novonesis delivered strong organic sales growth of 7% in 2025 COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.  Ester Baiget, President & CEO:  “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch